LENZ Therapeutics (NASDAQ:LENZ) Coverage Initiated at HC Wainwright

HC Wainwright started coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note released on Monday, MarketBeat reports. The firm issued a buy rating and a $38.00 target price on the stock. HC Wainwright also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.50) EPS, Q3 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.72) EPS, FY2024 earnings at ($2.59) EPS, FY2025 earnings at ($3.07) EPS, FY2026 earnings at ($3.26) EPS, FY2027 earnings at ($1.73) EPS and FY2028 earnings at $0.46 EPS.

A number of other equities research analysts have also issued reports on LENZ. Leerink Partnrs restated an outperform rating on shares of LENZ Therapeutics in a report on Monday, April 15th. William Blair assumed coverage on LENZ Therapeutics in a report on Monday, April 15th. They issued an outperform rating for the company. Finally, SVB Leerink started coverage on LENZ Therapeutics in a research report on Monday, April 15th. They issued an outperform rating and a $32.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of Buy and an average target price of $35.00.

LENZ Therapeutics Stock Down 3.8 %

LENZ stock opened at $22.60 on Monday. LENZ Therapeutics has a 12 month low of $14.07 and a 12 month high of $29.82. The company’s 50 day simple moving average is $20.59.

Hedge Funds Weigh In On LENZ Therapeutics

A number of institutional investors have recently modified their holdings of LENZ. American International Group Inc. bought a new position in shares of LENZ Therapeutics in the first quarter worth about $44,000. Marquette Asset Management LLC bought a new position in LENZ Therapeutics in the 1st quarter worth approximately $131,000. Squarepoint Ops LLC acquired a new position in shares of LENZ Therapeutics during the second quarter worth approximately $181,000. Rhumbline Advisers boosted its position in shares of LENZ Therapeutics by 265.6% in the second quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock valued at $291,000 after acquiring an additional 12,214 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of LENZ Therapeutics by 28.4% in the second quarter. Renaissance Technologies LLC now owns 60,166 shares of the company’s stock worth $1,040,000 after acquiring an additional 13,300 shares during the last quarter. Institutional investors own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.